AR029623A1 - Composiciones farmaceuticas de eritropoyetina - Google Patents

Composiciones farmaceuticas de eritropoyetina

Info

Publication number
AR029623A1
AR029623A1 ARP000101631A ARP000101631A AR029623A1 AR 029623 A1 AR029623 A1 AR 029623A1 AR P000101631 A ARP000101631 A AR P000101631A AR P000101631 A ARP000101631 A AR P000101631A AR 029623 A1 AR029623 A1 AR 029623A1
Authority
AR
Argentina
Prior art keywords
amount
erythropoietin
amino acid
oxy
derivative
Prior art date
Application number
ARP000101631A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR029623A1 publication Critical patent/AR029623A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion farmacéutica de eritropoyetina que comprende: (a) un agente regulador del pH; (b) una cantidad estabilizadora de un derivado de mono-9-octadecenoato poli(oxi-1,2-etandiilo) de sorbitán; (c) una cantidad estabilizadora de un aminoácido; (d) una cantidad farmacéutica de eritropoyetina; y en donde la formulacion no contiene urea o un producto sanguíneo humano. Formulaciones farmacéuticas acuosas de eritropoyetina que están libres de productos de sangre en suero humana, estabilizadas con una cantidad de un aminoácido y un derivado de mono-9-octadecenoato poli(oxi-1,2-etandiilo) de sorbitán. Se describen también formulaciones farmacéuticas conservadas y estables de eritropoyetina que contienen una cantidad antimicrobiana de cresol y una cantidad de un aminoácido.
ARP000101631A 1999-04-09 2000-04-10 Composiciones farmaceuticas de eritropoyetina AR029623A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12859699P 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
AR029623A1 true AR029623A1 (es) 2003-07-10

Family

ID=22436082

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101631A AR029623A1 (es) 1999-04-09 2000-04-10 Composiciones farmaceuticas de eritropoyetina

Country Status (27)

Country Link
US (2) US6696056B1 (es)
EP (1) EP1181036B1 (es)
JP (1) JP2002541208A (es)
KR (1) KR100740794B1 (es)
CN (1) CN1165339C (es)
AR (1) AR029623A1 (es)
AT (1) ATE401908T1 (es)
AU (1) AU775041B2 (es)
BG (1) BG106046A (es)
BR (1) BR0010665A (es)
CA (1) CA2369444C (es)
CY (1) CY1108418T1 (es)
DE (1) DE60039598D1 (es)
DK (1) DK1181036T3 (es)
ES (1) ES2308978T3 (es)
HK (1) HK1041445B (es)
HU (1) HUP0201068A3 (es)
IL (1) IL145816A0 (es)
MX (1) MXPA01010208A (es)
NO (1) NO20014893L (es)
NZ (1) NZ515380A (es)
PL (1) PL203797B1 (es)
PT (1) PT1181036E (es)
RU (1) RU2225221C2 (es)
TR (1) TR200103788T2 (es)
WO (1) WO2000061169A1 (es)
ZA (1) ZA200109236B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
IL145816A0 (en) * 1999-04-09 2002-07-25 Ortho Mcneil Pharm Inc Pharmaceutical compositions of erythropoietin
US7371787B2 (en) * 2000-04-14 2008-05-13 Viance, Llc Methods of incorporating treatment agents into wood based composite products
BRPI0110914B8 (pt) † 2000-05-15 2021-05-25 Hoffmann La Roche 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
BRPI0411114B8 (pt) * 2003-06-10 2021-05-25 Lg Chemical Ltd solução aquosa estável de eritropoetina humana, não contendo albumina de soro
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
CN1852700A (zh) * 2003-09-23 2006-10-25 爱尔康公司 曲安奈德和醋酸阿奈可他注射用制剂
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
CA2618068C (en) 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101015684B (zh) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 一种重组人红细胞生成素溶液制剂
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR100956431B1 (ko) 2007-12-07 2010-05-06 주식회사 제이에스마루 혈장크린접착제 및 이의 제조방법
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
EA201791717A1 (ru) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
JP2020522263A (ja) * 2017-06-06 2020-07-30 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のためのエリスロポエチンおよびアナログ
CN111150837B (zh) * 2020-02-11 2022-07-12 中国人民解放军陆军军医大学 Epo在抗金黄色葡萄球菌感染药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5543575A (en) * 1990-06-20 1996-08-06 Pioneer-Hi-Bred International, Inc. Inbred corn line PHK46
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
IL145816A0 (en) * 1999-04-09 2002-07-25 Ortho Mcneil Pharm Inc Pharmaceutical compositions of erythropoietin

Also Published As

Publication number Publication date
AU4218600A (en) 2000-11-14
EP1181036B1 (en) 2008-07-23
ATE401908T1 (de) 2008-08-15
JP2002541208A (ja) 2002-12-03
NO20014893D0 (no) 2001-10-08
PL203797B1 (pl) 2009-11-30
HK1041445A1 (en) 2002-07-12
US20040248797A1 (en) 2004-12-09
DK1181036T3 (da) 2008-11-24
NO20014893L (no) 2001-11-15
KR20020016770A (ko) 2002-03-06
CN1354669A (zh) 2002-06-19
TR200103788T2 (tr) 2002-05-21
CA2369444A1 (en) 2000-10-19
EP1181036A1 (en) 2002-02-27
WO2000061169A1 (en) 2000-10-19
PT1181036E (pt) 2008-10-03
BG106046A (en) 2002-05-31
HK1041445B (zh) 2009-07-03
US6696056B1 (en) 2004-02-24
HUP0201068A2 (en) 2002-08-28
KR100740794B1 (ko) 2007-07-20
CY1108418T1 (el) 2014-04-09
NZ515380A (en) 2003-10-31
AU775041B2 (en) 2004-07-15
ZA200109236B (en) 2003-12-08
CA2369444C (en) 2009-08-18
PL351837A1 (en) 2003-06-16
CN1165339C (zh) 2004-09-08
HUP0201068A3 (en) 2002-10-28
BR0010665A (pt) 2004-03-09
IL145816A0 (en) 2002-07-25
MXPA01010208A (es) 2003-07-21
EP1181036A4 (en) 2004-04-21
ES2308978T3 (es) 2008-12-16
RU2225221C2 (ru) 2004-03-10
DE60039598D1 (de) 2008-09-04

Similar Documents

Publication Publication Date Title
AR029623A1 (es) Composiciones farmaceuticas de eritropoyetina
BRPI0416160A (pt) composições de xampu antimicrobianas
DE60020716D1 (de) Filmbildende zusammensetzungen aus pullulan
BR0112094A (pt) Produtos de confeitaria contendo ingredientes ativos
ES2145836T3 (es) Copolimeros elastomericos termoplasticos injertados de silicona, y composiciones que los contienen para el cuidado del pelo y la piel.
DK1315479T3 (da) Pektin-filmkompositioner
PE11495A1 (es) Copolimero elastomerico termoplastico injertado con silicona y composicion para el cuidado del cabello y de la piel que lo contiene
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
CR8480A (es) Formulaciones veterinarias que contienen producto no animal
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
NO883926L (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
UA42028C2 (uk) ПРЕПАРАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ У ВИГЛЯДІ СТАБІЛЬНОГО ВОДНОГО РОЗЧИНУ
SI0991407T1 (en) Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
CA2286409A1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
PT1121144E (pt) Preparados de insulina concentrada estavel para administracao pulmonar
ATE197808T1 (de) In wässriger lösung redispergierbare polymerpulver
CO5570651A2 (es) Productos para la axila, con componente de bloqueo de agua
ES8503344A1 (es) Un procedimiento para preparar derivados de propinilaminoisoxazol
FR2804319B1 (fr) Composition cosmetique amincissante comprenant en tant qu'agent actif un extrait de plante contenant de l'anp
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
DE60017361D1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
CO4700420A1 (es) Formulacion transdermica
DE59807411D1 (de) Mittel zur behandlung keratinischer fasern
NO20011281L (no) Insekticid preparat
HN1999000135A (es) Formulacion liquida.

Legal Events

Date Code Title Description
FB Suspension of granting procedure